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ABSTRACT
In consideration of the on-going global pandemic, immediate access to Food and
Drug Administration approved pharmaceutical medications and vaccines is a matter of
utmost priority to our national healthcare system. One significant modality in managed
care is the dispensation of prescription drugs for the prevention or treatment of illnesses
and diseases. According to the Centers for Disease Control and Prevention, physicians
order and provide over 2.9 billion prescriptions each year with analgesics,
antihyperlipidemics, and dermatological agents being the most prescribed therapeutic
classes. Within those classes exists a disparate variety of chemical structures that must be
prepared on a metric ton scale to meet the continual societal demand.
The piperidine scaffold is very prevalent in many FDA approved drugs, making it
an important pharmacophore and essential in the field of drug discovery. Piperidines are
the building blocks for over 70 different types of commercial drugs, such as Ritalin and
Evista. The complexity of these structures along with the economic costs of sourcing all
the raw materials is a contributing factor to the increasing burden of prescription drug
costs. Therefore, by developing new chemical reactions to access the piperidine scaffold,
the economic and chemical challenges can be effectively managed to ensure healthcare
demands are met. The overarching goal of this project is to develop a robust catalytic,
asymmetric synthesis of piperidine rings from feedstock petrochemicals.
In an initial study of the N-sulfonyl iminium ion Pictet-Spengler cyclization with
N-para-toluenesulfonyl homoveratrylamine and 3-phenylpropanal, a screen of metal
triflates was examined. The hypothesis is that transition metal triflates are sufficiently
Lewis acidic to activate relatively inert sulfonamide nitrogen atoms to condense with
iv

aldehydes and trigger the intramolecular cyclization forming piperidines. Initial results
indicated that scandium (III), stannous (II) and copper (II) triflates gave the fastest
conversion to the N-sulfonyl piperidine, while triflates such as lanthanum (III), sodium
(I) and magnesium (II) gave little to no conversion under the allotted time. Further
examinations were made to study the steric effects of the aldehyde carbon chain and
hybridization, as well as the N-sulfonyl group substituent on cyclization conversion. A
second acid catalyst screen was conducted of the N-sulfonyl iminium ion Aza Prins/Ritter
reaction with N-sulfonyl homoallylic amine and 3-phenylpropanal to observe the
difference between Bronsted acids and Lewis acids on cyclization conversion.
The fundamental investigation of chemical reactivity for the synthesis of nitrogen
heterocycles from petroleum feedstocks has significant impact on societal healthcare
needs. The control of reaction variables such as catalyst and ligand architectures in
asymmetric transformations increases our understanding of interactions at the atomic
level. Additional studies have focused on the use of chiral ligands, such as PyBOX
ligands to induce asymmetry in the cyclization event. When screened against N-paratoluenesulfoyl homoveratrylamine with the successful metal triflates (scandium (III) and
copper (II)) under various solvents, preliminary results showed no conversion towards the
piperidine product. Future studies will focus on examining the kinetics of chiral ligand
mechanisms and increasing the reactivity of iminium ions.

Keywords: piperidine, Pictet-Spengler, pharmacaphore, transition-metal triflates,
asymmetric catalysis, enantioselectivity
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INTRODUCTION
Nitrogen Heterocycles
Nitrogen-based heterocyclic chemistry is one of the most important and unique
branches of synthetic organic chemistry, with research around the subject growing in
popularity over the past decade. Being an integral component of over half of all United
States Food and Drug Administration (FDA) approved small-molecule drugs, nitrogen
heterocycles possess physiological and pharmacological properties that are widely
beneficial as structural
components of biologically

Table 1: Nitrogen Heterocycles in Common
Pharmaceuticals
Structure

important molecules, such as
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2014, the authors provided an in
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depth compilation of the

H
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frequency of different types of

nitrogen heterocycles among US FDA approved pharmaceuticals, as well as an analysis
of the structural diversity and substitution patterns among them. In 2014, there were a
total of 1035 FDA-approved unique small-molecule drugs. Among those, 874 molecules
have structures that contain a nitrogen atom, with 613 of those molecules containing a
nitrogen heterocycle. In addition to the 27 nitrogen-heterocyclic combination drugs (two
1

or more active ingredients in single dosage form), there were a total of 640 smallmolecule drugs that contain nitrogen heterocycles, making the motif prevalent in 59% of
all unique small-molecule drugs.2 According to the FDA database, there are currently
3,568 domestic US FDA-approved drugs, with 2684 total approved small molecule drugs.
Nearly 75% of these unique small molecule drugs contain a nitrogen heterocycle.
Moreover, many drug molecules consist of more than one nitrogen per molecule, with the
average being 2.3 N/ drug for all small molecule drugs and 3.1 N/ drug for nitrogen
heterocycle-containing drugs.2
Many heterocyclic scaffolds can be considered privileged structures, which are
molecular scaffolds with versatile binding properties. 3 The central role of heterocycles in
modern drug design is widely due to recent advances in synthetic methodologies, such as
metal-catalyzed cross-coupling and hetero-coupling reactions that allow for rapid access
to a wide variety of functionalized heterocycles.4 Moreover, many heterocyclic
pharmaceuticals are isolated from natural resources, with their structures being simplified
and modified in the drug manufacturing process.
Within the top 25 most utilized nitrogen heterocycles in US FDA-approved drugs,
five six-membered ring (SMR) structures can be found in the majority of drugs: (1)
piperidine, (2) pyridine, (3) piperazine, (4) phenothiazine, and (5) pyrimidine (Table 2).
Table 2: Top 5 Six-Membered N-Heterocycles
R
N

S
N
R

N

phenothiazine

pyrimidine

N
N
R

N

N
R

piperidine

pyridine
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2

Aromatic rings are a common and very powerful motif in drug discovery due to
their unique mode of interaction with target proteins. However, six-membered
nonaromatic rings are the most prevalent structure found in all FDA-approved
pharmaceuticals, with piperidine and piperazine being the most common.
Piperidines
Piperidines are ranked the most frequent nitrogen heterocycle of all US FDAapproved drugs, making up 72 unique small molecule drugs.2 Piperidines are SMR
structures with five carbon atoms and one nitrogen atom, and
have a wide range of practical and therapeutic applications
such as antipsychotics and analgesics (Figure 2). Piperidines
often occupy small molecule pharmaceuticals as a
centralized scaffold to which different substituents can be
attached (Figure 1). The N1 and C4 positions of the

86%
4% 6 N 1
5

7%

33%
2

4

3

19%

58%

Figure 1: Piperidine
Ring Substituent
Pattern

piperidine are strongly favored, meaning that they are the
most likely to contain a substituent para to the nitrogen atom. This is followed by the C2
and C3 positions, and finally the C5 and C6 positions, which are very rarely substituted.
Additionally, the piperidine ring is more likely to be disubstituted than monosubstituted,
with 1,4-disubstitution occurring 39% of the time.2 The diversity in the structure and
substituting pattern of the piperidine scaffold in pharmaceuticals classifies the structure
as a privileged moiety that has the ability to provide potent and selective ligands for a
range of different biological targets.2
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Figure 2: Relevance of Piperidine Scaffold
New Drug Market
A 2016 study stated that global net spending on prescription drugs increased 20%
between the years 2013 and 2015, now comprising 17% of total healthcare costs. 5 In
contrast to other countries, the United States spends over $800 per capita per year on
prescription drugs, as opposed to an average of $400 by other highly industrialized
nations.6 The United States has the highest-grossing revenue for their top 20 prescription
drugs, which is almost 3 times greater than that in the United Kingdom.7 The top 20 bestselling pharmaceuticals account for 15% of global pharmaceutical spending, allowing
private pharmaceutical companies such as Pfizer, Roche, and Merck to turn a high profit
and monopolize the US pharmaceutical market.7 Prices for the top brand-name drugs in
the U.S. increased by nearly 130% between 2008 and 2014, creating a competitive
marketplace that is completely controlled by private companies. Manufacturers aim to
4

turn a quick profit, and with the US having the highest chronic disease burden and
obesity rate, it is almost instantaneous that new drugs in these high-value therapeutic
regions will earn a lucrative profit.8 High drug costs require patients, regardless of their
insurance plan, to pay inflated co-payments for their medications, thus affecting
immediate and affordable access to prescriptions leading to consequential negative health
outcomes.5 Therefore, the need for new, cost-effective and time-efficient synthetic
methodologies to produce precious prescription drug moieties is more prominent than
ever.
Due to exorbitant research and development (R&D) costs to bring a new drug to
the market, as well as continuing tightening federal regulations, the rate of new
pharmaceutical drugs entering the market is slowly decreasing. The average time between
clinical testing for a new drug until marketing approval is approximately 97 months or 8
years.9 The cost of drug development can range anywhere from $157.3 million to $1.95
billion, without considering opportunity costs.10 Moreover, the total amount of money
that pharmaceuticals have contributed to R&D costs consistently increases each year,
ranging from $15 billion in 1995 to approximately $40 billion in 2005.11
Furthermore, new molecular entities (NME) that were introduced to the market in
recent years lack the market revenue stream of previous drugs. From 1990 to 1994, 11
new market drugs reached the top 100 drugs in terms of global revenue.11 However, from
2000 to 2004, only two new markets drugs were able to receive the distinction of “top
100 drugs.” This can be attributed to the fact that only 11.8% of experimental drugs
succeed during clinical trials, while a vast majority fall short after several years in
development.11 Market oversaturation and competition have increased the burden on drug
5

innovation; it is becoming harder to develop a "new" and novel medication that will
thrive in the market. Therefore, it is more relevant than ever to discover new synthetic
methods for innovative pharmaceutical moieties that are cost-effective and time efficient
to capitalize on gross revenue profit, make up for lost revenue of failed drugs, and be able
to provide lifesaving drugs to those who may not be able to afford the current market
price.
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BACKGROUND
Iminium Ions
The synthesis of N-heterocycles is growing increasingly popular in recent years,
as it is becoming ever important to continue developing new pharmacophores as diseases
and viruses continue to emerge and mutate. Equally important to nitrogen heterocycle
synthesis is the understanding of iminium ions and their reactivity, spatial arrangement,
and electrophilicity in reaction mechanisms. Iminium ion cyclizations, such as the PictetSpengler cyclization, are a widely studied area of alkaloid chemistry to create carboncarbon bonds between the α carbon and the basic nitrogen and an aromatic ring (Scheme
1).12 Iminium
ions are obtained
by protonation
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Scheme 1: N-Sulfonyliminium Ion Research Design

aldehydes. These
cations adopt alkene-like geometries, in which the C=N unit is coplanar with all four
substituents and cis/trans isomers can be observed. Imines and their derivatives play a
significant role as key intermediates in many natural processes, especially for synthesis of
7

nitrogen heterocycles. Many enzymes employ imines as part of their reaction mechanism,
such as the coenzyme pyridoxal phosphate (PLP) which forms an imine bond between an
amino acid carbonyl group and the amine of lysine.
Enantiomers
One particularly challenging aspect of medicinal chemistry is the formation of
stereoisomers. Stereoisomers are molecules that have the same chemical formula but
differ in spatial arrangement of their atoms. Specific stereoisomers referred to as
configurational isomers are molecules of different configurations that cannot be made
superimposed by any rotations around single bonds and can be interconverted only by
breaking bonds. Chirality describes a property of a molecule to be asymmetric in the way
that its structure and mirror image are inequivalent. This is equivalent to a left hand–right
hand relationship, in which each hand is a mirror image of the other and both cannot be
superimposed (thumbs will not overlap if both hands are placed palm-up.) Molecules can
be considered to have a chiral center if all the surrounding atoms are not equivalent.
Enantiomers are configurational stereoisomers that are non-superimposable mirror
images of a compound (Figure 3).
enantiomers

C
R

H

H

MeO

O
R

C

H
R N

S

mirror image
carbon isomers

R-methylphenidate

Figure 3: Stereoisomers and Ritalin Example
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Enantiomers are pairs of chiral stereoisomers that will have a 1:1 ratio of each
pair in a molecule, called a racemic mixture. More than half of the currently marketed
pharmaceutical drugs are chiral compounds with almost 90% marketed as racemates
consisting of equimolar mixtures of two enantiomers. For example, Ritalin, which is a
central nervous stimulant used to treat diseases such as attention deficit disorder,
attention deficit hyperactivity disorder, and narcolepsy, is sold as a racemic mixture of
both the R and S enantiomer (Figure 3). This can be problematic, because many existing
routes used to produce piperidines are not stereoselective and yield racemic compounds
that may be deleterious due to unknown pharmaceutical activity. One enantiomer of a
prescription drug may be the biologically active medicine for a particular disease, while
the other enantiomer may be not only inactive but also toxic. Therefore, synthesizing
compounds as a single enantiomer is crucial in the synthesis design of new prescription
drugs.
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RESEARCH DESIGN
The overarching goal of this project is to develop a robust catalytic, asymmetric
synthesis of piperidine rings from inexpensive petroleum feedstock chemicals. Small
molecules derived from nature serve as a rich source of many pharmaceuticals,
specifically anticancer agents and antibiotics. My role in this research project mainly
focuses on the use of the Pictet-Spengler cyclization and the Aza Prins/Ritter addition
mechanism to form these piperidines. By utilizing commercially available aldehydes and
sulfonamides, unnecessary costs can be eliminated and the iminium ion’s effect on
producing a racemic mixture can be explored.
Pictet Spengler Cyclization
In the Pictet-Spengler Cyclization reaction (Scheme 2), an amine 1 undergoes
cyclization with an

aldehyde
X
activation H

aldehyde 2 followed by a
ring closure to the
tetrahydro isoquinoline 8.
The mechanism begins
with the protonation of the
aldehyde carbonyl oxygen

X
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H
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H
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R N
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R2 S N
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2 by the acid, resulting in
Scheme 2: Pictet-Spengler Cyclization Mechanism
the oxonium ion, which
subsequently is attacked by the sulfonamide nitrogen 1. After a series of proton transfer
steps (3→4 and 4→5), a water molecule (5→6) is released, which results in a protonated
imine intermediate 6-Z or 6-E. The molecule then undergoes a 6-endo-trig cyclization
10

reaction (6→7) with loss of aromaticity of the aryl ring. A final deprotonation step by the
conjugate base of the acid restores the aromaticity and results in the equal production of
tetrahydroisoquinoline products 8-R and 8-S, a racemic mixture.
This reaction can be modified by adding an electron withdrawing group such as a
toluenesulfonyl to the R1 position on the amine thus removing electron density and
making the amine hydrogen more acidic (Scheme 3). Acid catalysts are commonly used
in this cyclization to further lower the energy difference between the nucleophilic amine
and electrophilic aldehyde, causing the electrophilic iminium ion to undergo the reaction.
Aldehydes and sulfonamides will condense to form two electrophilic N-sulfonyliminium
ions that differ in their relationship across the C=N pi bond, which can be trapped by the
aromatic ring system within the molecule. As with Ritalin (Figure 3), the two resulting
cyclization products are mirror images of one another.
Feedstock Chemicals
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Scheme 3: Research Design for the Synthesis of Nitrogen Heterocycles

Whereas the utility of N-acyliminium ions has been thoroughly investigated, there
is little information on the reactivity of the N-sulfonyliminium ion. In theory, nitrogen
sulfonamides have inherently low nucleophilicity, making these reactions difficult to
proceed in normal conditions. Therefore, when a Lewis acid catalyst is used in
11

intramolecular cyclization reactions, it bonds to the oxygen atom in aldehydes; this
activates the molecule by making the central carbon more electrophilic and allows
reactants with low nucleophilicities, such as nitrogen sulfonamides, to undergo
nucleophilic attack. Lewis acids such as scandium trifluoromethanesulfonate are highly
oxophilic and form a strong but easily altered bond with oxygen atoms. Moreover, they
allow the reaction to be carried out in mild conditions with high yields of the final
product. The bond between the oxygen-Lewis acid structure eventually breaks, causing
the Lewis acid to leave and reforming the catalyst for subsequent reactions.
Homoveratrylamine, also known as dimethoxyphenethylamine (DMPEA), is an
analog of the neurotransmitter dopamine in which the 3- and 4- position hydroxy groups
have been replaced with methoxy groups. DMPEA occurs naturally in various species of
cacti and has some known pharmaceutical activity as a monoamine oxidase inhibitor. 13
Sulfonamides derived from homoveratrylamine have been shown to cyclize with
aldehydes and acetals with Bronsted acids and Lewis acids in non-coordinating solvents.
By utilizing para-toluene sulfonamides as opposed to methane sulfonamides, the methyl
signature of the toluene allows for easy identification in 1H NMR. Moreover, methyl
protons are inherently acidic and can undergo condensation reactions under the proposed
conditions. The challenge of this research is controlling the following factors: (i)
equilibrium in the formation of the ions 11a and 11b; and (ii) the addition of the
nucleophile to the face of the iminium ion. The hypothesis for this project is that
transition metal triflates are sufficiently Lewis acidic to activate aldehyde carbonyl
groups to undergo attack by relatively inert sulfonamides, triggering the nitrogen for
intramolecular cyclization forming piperidines. Any successful transition metal triflates
12

will then be screened with various chiral ligands to introduce asymmetry into the
cyclization event.
Aza Prins/ Ritter Reaction
The second portion of this project will focus on the Aza Prins/ Ritter reaction of
N-sulfonyl homoallylic amines, which gives direct access to the piperidine skeleton with
the addition of a nucleophile at the C4 position (Scheme 4). The Aza Prins reaction
begins with the condensation of homoallylic amine 13 with an aldehyde 14 in the
presence of an acid to give an iminium ion 18-Z or 18-E, which then undergoes the
intramolecular nucleophilic attack by the olefin.14 A Ritter addition is then performed, in
which a nitrile and carbocation precursor will convert to amide 21-R or 21-S using a
strong acid and water. The reaction proceeds by the electrophilic addition of the
carbocation 19 to the nitrile. The resulting nitrilium ion 20 is hydrolyzed by water to the
aldehyde
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Scheme 4: Aza Prins/ Ritter Mechanism
desired amide.15 In theory, sulfonamide nitrogen is more nucleophilic than amide
nitrogen, due to resonance with the carbonyl oxygen. Both the oxygen and the nitrogen in
amides are sp2 hybridized, which causes the lone pairs on nitrogen to be delocalized and
in resonance with the p orbital of the C=O double bond. Amide bonds are very stable due
13

to the near-perfect overlap of their p orbitals, which significantly reduces the partial
positive charge on the carbonyl carbon, thus making it less electrophilic. Therefore, the
hypothesis for this project is that secondary sulfonamides should readily condense with
electrophilic aldehydes in the presence of acid to generate an N-sulfonyliminium ion.
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GENERAL LABORATORY TECHNIQUES
Materials
Starting materials were purchased from commercial vendors and checked for
identity and purity using IR, NMR and HPLC and were used without purification unless
noted.
Methods
To monitor reaction conversion and progress, we employed the use of thin-layer
chromatography (TLC), high-performance liquid chromatography (HPLC), and nuclear
magnetic resonance spectroscopy (NMR) as analytical methods. Solvent removal was
effected using a Buchi R3 rotary evaporator with a V900 diaphragm pump (~ 10 mmHg).
All yields refer to isolated material that is chromatographically (TLC or HPLC) and
spectroscopically (1H NMR) homogeneous. Further descriptions of individual methods
and how they were utilized have been included below.
Pictet-Spengler Methods
All reactions were left to stir for 24 hours and monitored via TLC (100%
dichloromethane) on regular phase silica gel by observing the disappearance of the
sulfonamide spot in the reaction mixture lane. The piperidine product formed a new spot
at Rf 0.58, with excess aldehyde and acid catalyst also being observed towards the
solvent line. Upon completion, the reaction mixture was diluted with dichloromethane
(DCM) and saturated aqueous sodium carbonate and stirred vigorously for one hour. The
organic layer was then separated, dried with magnesium sulfate, and gravity filtered
before concentration via rotary evaporator. The reaction mixture was then analyzed by 1H
NMR to determine the percent conversion and identify the product.
15

Aza Prins/Ritter Methods
The reaction was monitored via TLC (4:1 hexanes-ethyl acetate) on regular phase
silica gel and then quenched upon completion with 1N HCL and left to stir for 1 hour.
The organic phase was then separated, dried with magnesium sulfate and vacuum filtered.
The reaction mixture was analyzed by 1H NMR to calculate conversion and determine the
reaction product.
Thin Layer Chromatography
Thin layer chromatography (TLC) is a chromatographic technique used to
separate components of a mixture using differences in the components' affinities for the
mobile and stationary phases. TLC plates (chromatoplates) made of silica gel act as the
stationary phase, while a solvent of choice acts as the mobile phase. The choice of
solvent used in TLC is guided by two factors: the polarity of the constituents to be
separated and the nature of the process involved. The retention factor (Rf) describes the
ratio of the distance migrated of a compound over the total distance of the solvent.
Considering the Rf value is a ratio, individual compounds will have unique Rf values
independent of the mobile phase. When comparing two different compounds under the
same conditions, the compound with the larger Rf value is less polar because it is carried
by the mobile phase a longer distance, while the smaller Rf value is more polar because it
“sticks” to the stationary phase and is carried a shorter distance (Figure 4).
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On an analytical scale, TLC can be used to monitor the progress of a reaction by
observing the appearance of
a product or disappearance

Solvent Front
less polar molecule
elution

of a reactant at different

more polar molecule
Start

points in the reaction
progress. Typical TLC

Figure 4: TLC Process

plates have three lanes: the
reactant, the reaction mixture, and a “cospot” where the reaction mixture is spotted
directly on top of reactant. Small aliquots (10-6 g) of a sample can be analyzed by TLC to
monitor reaction conversion at distinct time intervals and give insight to the progress of a
reaction. Analytical thin layer chromatography was performed using Sorbent
Technologies 250 m glass-backed UV254 silica gel plates. The plates were first
analyzed under 254 nm irradiation by UV light, then stained with phosphomolybdic acid
followed by heating.
High Performance Liquid Chromatography
High Perfromance Liquid Chromatography also uses the principle of
chromatography to separate components of a mixture based on polarity; however, this
technique offers more resolution and computer integration to quantitively measure the
reaction progress. Mechanical pumps are used to pump pressurized liquid (mobile phase)
into the system and an injector introduces the sample into the mobile phase. The sample
then enters the column (stationary phase) at a constant flow rate, and the mobile phase
acts as a carrier through the column. A compound that is more polar will adhere to the
stationary phase, thus eluting from the column later than compounds that are less polar.
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This method is used to separate biproducts, intermediates, starting material, and major
products from the reaction mixture.
Nuclear Magnetic Resonance Spectroscopy
Nuclear Magnetic Resonance Spectroscopy (NMR) has become the preeminent
technique for determining the structure of organic compounds by observing local
magnetic fields around atomic nucleic. The principle of NMR is that nuclei of elemental
isotopes have characteristic spins that are electrically charged. This spinning generates a
magnetic field that has a magnetic moment (μ) proportional to the spin. In the presence
of an external magnetic field (β0), energy transfer occurs between the base energy to a
higher energy level, causing energy to be emitted when the spin returns to base level.
Two spin states exist, with the magnetic moment of the lower energy state aligned to the
external field, and the higher energy spin state opposed to the external field. For spin ½
nuclei, the energy difference between the two spin states at a given magnetic field is
proportional to their magnetic moments. For common nuclei, such as 13C, 1H, and 19F, the
spin state energy separations can used to predict their approximate frequencies. The
NMR spectrometer can differentiate between elements and isotopes because the specific
nuclei will absorb at different frequencies, meaning that NMR can be “tuned” to specific
nuclei. In this project, we will solely utilize 13C, 1H, and two-dimensional NMR
techniques on a 400 MHz NMR for the analysis of organic molecules and measurement
of conversion from starting material to product.
The principle behind proton NMR (1H NMR) is that each unique hydrogen nuclei
in a compound exhibits a predictable precession in a magnetic field. This generates a
calculatable peak on the computerized spectrum, which can be used to elucidate the
18

structure of compounds in a sample. Hydrogens in different chemical environments will
resonate at slightly different frequencies, causing them to “shift” on the spectra. This is a
result of the atom’s nucleus being either deshielded (downfield shift) or shielded (upfield
shift) (Figure 5). Two main factors influence chemical shift: (1) deshielding effects due
to reduced electron density, and (2) anisotropy (due to magnetic fields generated by π
bonds). Chemical shifts can be used to identify structural properties in a molecule by
analyzing differences in chemical environments. Moreover, integration can be used to
identify the relative ratio of H atoms that a peak represents
Downfield

Upfield

Deshielded

Shielded

Higher Frequency

Lower Frequency

Figure 5: NMR Chemical Shift
Unlike 1H NMR, there is no integration and signal splitting in 13C NMR, due to
the low natural abundance (1%) of the 13C isotope. In consequence, carbon NMR signals
are relatively weaker and no carbon-carbon splitting is observed. However, proton-carbon
splitting by neighboring hydrogens does occur, which often leads to complicated splitting
patterns. Due to this effect, a proton-decoupled NMR is commonly used, which
eliminates the signal splitting and reduces the 13C peaks to individual singlets. Following
this experiment, two distortionless enhancement by polarization transfer (DEPT) are run
to determine the multiplicity of carbon nuclei (primary, secondary or tertiary.) DEPT135
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experiments differentiate between CH, CH2, and CH3 groups by orienting the CH and
CH3 peaks up while CH2 peaks point down. To differentiate between CH and CH3 peak,
a second experiment called DEPT90 is used to isolate the CH peaks exclusively, allowing
for the identification of CH peaks from the DEPT135 spectra.
Two-dimensional NMR techniques such as homonuclear correlation spectroscopy
(COSY), heteronuclear single quantum correlation (HSQC), and heteronuclear multiple
bond correlation (HMBC) were also used in the elucidation of structures. COSY
correlates chemical shifts of coupled hydrogen nuclei between vicinal protons. The 1H
NMR spectra is plotted both axis, which reveals information about the scalar coupling
and can help resolve the structure of the molecule. On the other hand, HSQC is used to
determine proton-carbon single bond correlations. The resulting spectrum has one axis
for proton (1H) and one axis for carbon (13C), resulting in a peak for each unique proton
attached to a heteronucleus. HMBC experiment give correlations between carbons and
protons that are separated by multiple bonds, much like proton-proton connectivity in
COSY. This spectrum is similar to HSQC in that the horizontal axis bears the 1H NMR
and the vertical axis bears the 13C NMR, but the proton-carbon cross-peaks are generated
from 1H - 13C correlations two, three, and four-bond distances away. The intensity of the
cross peaks depends on the coupling constant, which follows the Karplus relationship.
This allows for chains of atoms and their overlapping partners to be elucidated from one
proton signal, and consequently, the chemical structure can be identified.
Proton nuclear magnetic resonance spectra were recorded on a Bruker UltraShield
Plus 400 MHz spectrometer and are recorded in parts per million from internal
chloroform (7.26 ppm) on the  scale and are reported as follows: chemical shift
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[multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, qu=quintet, m=multiplet),
coupling constant(s) in hertz, integration, interpretation]. 13C NMR data were recorded
on a Bruker UltraShield Plus 400 MHz spectrometer and are reported as follows:
chemical shift (multiplicity as determined from DEPT (CH, CH3 up and CH2 down)
and/or HSQC experiments.
After elucidation of the structure by NMR, each product sample was placed into a
Fourier-transform infrared spectrometer (FTIR) equipped with an attenuated total
reflectance (ATR) attachment to measure the absorption of electromagnetic radiation.
FTIR is a technique used to obtain an infrared spectrum of the absorption or emission of a
solid, liquid or gas by using Fourier transform (a mathematical process) to convert raw
data into spectra. ATR is a sampling technique used alongside infrared spectroscopy to
qualify the sample to be observed directly in the solid or liquid state. FTIR relies on the
basis that when introduced to infrared radiation, molecules will vibrate. Covalent bonds
will absorb and vibrate at a specific frequency, allowing for the identification of potential
functional groups. FTIR spectrometers simultaneously collect high-resolution data over a
broad spectrum, which proves significant advantage as opposed to a dispersive
spectrometer, which measures intensity over a narrow range of wavelengths at a time. 16
This method allows for the identification of specific functional groups within the
molecule, further aiding in the elucidation of chemical structures.
High resolution mass spectrometry (HRMS) can be used to distinguish between
compounds of the same nominal mass, determine elemental compositions, and identify
unknowns.17 Mass spectrometry measures the mass-charge ratio (m/z) of an analyte by
accelerating positive-charged ionized molecules and deflecting them by a magnetic field.
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The beam of ions passing through the machine is then detected, and fragmentation of the
molecule are recorded at their corresponding m/z. These fragments act as "puzzle
pieces"to help identify the structure of the compound. High-resolution mass spectra were
recorded either the Old Dominion University College of Science Major Instrumentation
Center (COSMIC) on a Bruker 12 Tesla APEX-Qe FTICR-MS with an Apollo II ion
source.
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RESULTS
Acid Screen of Pictet-Spengler Cyclization with Sulfonamides
To begin the synthetic route, we examined Lewis acids, specifically metal triflates
as promoters in the formation of N-sulfonyliminium ions. Recent studies have examined
the strong electron-withdrawing ability of triflates to produce an electron-deficient metal
cation, which renders strong Lewis acidity for the activation of the aldehyde C-O double
bond.18 N-para-toluenesulfonyl homoveratrylamine 10 was reacted with the test aldehyde
3-phenylpropanal 22 and screened against different metal triflates to determine the steric
effect of the sulfonamide moiety on imine activation.
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HN

O
O
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N

22
O
(1.2 equiv)

MeO
OMe

Triflate metal (0.1 equiv)
CH2Cl2 (0.3M)
r.t., 26 hrs.

10

MeO
12

OMe

Scheme 5: Pictet-Spengler Cyclization with 3-Phenylpropanal
Initial results showed fastest and complete conversions to the cyclized piperidine
product with Sc3+, Sn2+, and Cu2+ triflates. Meanwhile, triflates of alkali and alkaline
earth metals, such as Na+ and Mg2+ gave little to no conversion to the piperidine product
under the allotted time (24 hrs.) The fastest conversions were observed in polar noncoordinating solvents such as dichloromethane, compared to non-polar solvents such as
hexanes and toluene. Solvents such as ether or tetrahydrofuran containing lone-paired
oxygen resulted in sluggish conversions, presumably due to the oxygen coordinating with
the electrophilic metal.
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Based on NMR verification, ring closure to the tetrahydroisoquinole product
occurred at the ortho position, which showed a characteristic proton peak at ~ 4.98 ppm
(Figure 7). This peak appeared as a doublet of doublets (dd), which is due to the 3J
coupling of the neighboring diastereotopic CH2 group in the ethylbenzene chain. Further,
the original sulfonamide 10 showed three aromatic protons in the dimethoxy benzene
ring: one doublet of doublets (6.62 ppm) and two doublets (6.72 ppm; 6.57 ppm), while

O
O
S
N
Aromatic
protons

MeO

Alpha
carbon

OMe

O
O
S
HN
a

MeO
OMe

Amide
proton

Figure 8: 1H NMR Stack Plot of Tetrahydroisoquinoline Product vs.
Homoveratrylamine
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the cyclized product showed only two singlets at 6.45 ppm and 6.32 ppm, thus indicating
the loss of meta-coupling by proton a.
Investigation of N-sulfonyl Group of Homoveratrylamine
Upon finding that metal triflates are successful acid catalysts in the cyclization, a
derivation of the sulfonamide group was investigated to determine the substitution effects
on the cyclization (Scheme 6). Preparation of the new sulfonamides was conducted by
the tosylation of homoveratrylamine with R-substituted sulfonyl chloride in the presence
of triethylamine (TEA) and DCM.

H2N
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HN
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R
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S
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MeO
OMe

Et3N (1.2 equiv)
CH2Cl2 (0.3 M)
r.t., 24 hrs.

23

MeO
OMe
24a-f

Scheme 6: N-Sulfonyl Group Screen
Further studies examined how the N-sulfonyl group influenced conversion to the
tetrahydroisoquinoline product. Scandium (III) triflate was used as the Lewis acid
catalyst (0.1 equivalent) for the cyclization of the N-sulfonamides 24a-f with 3phenylpropanal 22 in the presence of DCM at room temperature. All reactions were left
to stir for 24 hours and were monitored via TLC for reaction completion. 1H NMR
allowed for analysis of conversion by calculating the ratio of the aromatic dimethoxy
protons, as well as the disappearance of the sulfonamide NH peak. Results found that
sulfonamides containing heteroatoms showed little to no conversion to the piperidine
product, presumably due to competition with the aldehyde as a Lewis base (Figure 9).
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Figure 9: Results of N-sulfonyl Group Screen with 3phenylpropanal

rather than the aldehyde
oxygen. Only
sulfonamides with carbon-

based substituents were shown to perform the cyclization, except for sulfonamide 24f,
which showed decreased conversion due to the steric hindrance of the tert-butyl group.
Steric hindrance is the prevention of inter- or intramolecular interactions as a result of the
spatial structure of a molecule.
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Aldehyde Screen of Pictet-Spengler Cyclization with Sulfonamides
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Scheme 7: Aldehyde Screen of Pictet-Spengler Cyclization

Considering that activation of the aldehyde is the initial step of the cyclization, a
substrate screen of aldehydes was performed to test the steric effects of changing the “R”
substituent at the alpha carbon on aldehyde reactivity. Both enolalizable and nonenolizable aldehydes were examined to determine if the high reactivity of the electronrich enol form is a major contributor to the cyclization event, or if the reaction can
proceed through a non-activated keto form. Many aldehydes have a neighboring carbon
H
O

O
H a
H R
keto

H

H

Nu

H

O
Ha

H

H R

H R

H
H

O
H

H
H

R
enol

Scheme 8: Mechanism for Keto-Enol Tautomerism
bearing at least one hydrogen atom, referred to as the alpha hydrogens. These hydrogens
can be removed easily through resonance stabilization, which causes the negative charge
to be shared between the alpha carbon and the oxygen, forming an enol. However, if
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there are no alpha hydrogens attached, the enol cannot form, and the reaction may
proceed differently.

In this screen, aldehydes of varying carbon chain lengths and substituents were
reacted with N-paratoluene homoveratrylamine with Sc(OTf)3 (0.1 equiv) in the presence
of DCM. Initial results found that sp3 carbons next to the aldehyde were successful in
performing the cyclization, while sp2 carbons next to the aldehyde were not successful
(Figure 10). This means that the activation of the aldehyde from keto to enol form is
necessary in the cyclization event to provide an electrophilic carbon center for the
nucleophilic nitrogen to attack. Exceptions include pivalaldehyde 25h, which could be
recalcitrant to the cyclization due to the steric hindrance caused by the bulkiness of the
tert-butyl group
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Figure 10: Tolerance of Aldehyde Group
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Acid Screen of Aza Prins/Ritter Reaction
O
O
S
N

22
O
O
S
HN

O
(1.2 equiv)
Acid (1.0 equiv)
CH3CN (0.3 M)
r.t., 24 hrs

26

HN

27

O

Scheme 9: Acid Screen of Aza Prins/Ritter Reaction
To test the hypothesis that N-sulfonyl homoallylic amines will readily condense
with aldehydes, an acid catalyst screen was performed with both Bronsted-Lowry acids
and Lewis acids as promoters for the formation of the N-sulfonyliminium ion. N-tosyl
homoallylic amine 26 was coupled with 3-phenylpropanal 22 in the presence of 1.0
equivalence of test acid and acetonitrile at room temperature.
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Figure 1: Crude NMR of Aza Prins/Ritter Reaction with CH3SO3H
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The crude sample was then analyzed by 1H NMR (Figure 11), which showed
several new peaks at 5.9 ppm, 4.8 ppm, and 4.2 ppm that were indicative of the N-tosyl
piperidine amide formation shown in Scheme 9. The disappearance of the peaks at 5.6
ppm, 5.1 ppm, and 4.5 ppm were indicative signals of a successful cyclization, although
resolving the peaks were near impossible in the current conditions. It was anticipated that
the cyclization would not be stereoselective and the generation of diastereomers would be
observed, resulting in a remarkably complex 1H NMR. However, the complication of the
crude spectrum gave insight that another product was being formed in the addition
reaction and that purification was needed to separate the two products.
Initial results of the acid screen showed that strong Bronsted acids produced the
best conversion to the piperidine product as compared to weak Bronsted acids (Figure
12). In general, strong Bronsted acids have relatively small or negative pKa values,which
measures how tightly protons are “held” by the molecule. The lower the pKa value, the
more H+ ions will dissociate in solution, and the stronger the proton donator. Sulfonic
acids 28a-d are very strong
Bronsted acids because
their conjugate bases
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Figure 12: Bronsted Acid Screen Results of AzaPrins/Ritter Reaction
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inherently “stronger,” due to their number of resonance-stabilized conjugate bases. From
this methodology, as well as the pKa values listed in Figure 12, we can infer that
stronger acids more readily protonate the aldehyde for activation, thus allowing for the
formation of the N-sulfonyliminium ion.
Based on success from the Pictet-Spengler reaction, metal triflates and metal
chlorides were examined to determine if Lewis acid catalysts are able to coordinate to the
nucleophilic carbonyl oxygen to protonate the aldehyde for activation. Lewis acidity
measures the strength of an acid by the tendency of the compound to accept a pair of
electrons. Lewis acids contain an empty orbital that is capable of accepting an electron
pair from a Lewis base, which has a filled bonding orbital containing an electron pair in a
nonbonding orbital. Preliminary results indicated that in 0.1 equivalence, only Sc(OTf)3
was able to give modest conversion (30%) to the piperidine product, while Cu(OTf) 3,
FeCl3, GaCl3, and NbCl5 showed no conversion. It was hypothesized that the low
concentration of acid may influence the availability of free orbitals for the carbonyl
oxygen to coordinate to. A second screen was then performed with 0.2 equiv of acid
catalyst and 1.0 equiv. of 3-phenylpropanal to increase the ratio of free orbitals to
available electrons. 1H NMR analysis showed a slight overall increase in percent
conversion for all screened acids (> 40% conversion); however, much of the reaction
mixture was still starting material, indicating that the reaction was not proceeding
successfully towards the piperidine product.
Comparing the results of the two acid screens, Bronsted acids were much more
successful in activating the aldehyde for cyclization. This may be explained by pKa
arguments, in which a Bronsted acid becomes negatively charged once deprotonated by
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the aldehyde. This negatively-charged conjugate base is present in solution and is later
used in the deprotonation of the ammonium ion 15. If the acid is unable to protonate the
aldehyde, the carbonyl carbon becomes less electrophilic and may not be attacked by the
amine reagent. Moreover, if deprotonation of the ammonium ion does not occur, the
reaction can proceed in the reverse direction and reform the starting material.
Ritter Additions vs. Acid Additions
Proton NMR analysis indicated a surprising byproduct from the Ritter addition of
the acetonitrile. The crude NMR showed an unexpected proton peak ~ 4.8 ppm, as well as
high-value integrations that did not correlate to the expected hydrogen count. The reaction
mixture was then purified by High Performance Liquid Chromatography (HPLC) which
allowed for separation of the piperidine product and the cyclization byproduct. The two
samples were characterized by 1H NMR, 13C NMR, 2D NMR, and mass spectrometry to
identify their chemical structures.
Analysis showed that the byproduct of the

Me
O
S O
N

reaction was due to the acid catalyst adding para to the
amine nitrogen at the secondary carbocation formed
from the Aza Prins reaction (Figure 13). Excess
conjugate base in solution can attack the electrophilic
carbocation by donating a pair of electrons in the

Ha
Hb
R = Acid

R

H

Hc
Hd

27a

Figure 13: Acid Addition
Product

nonbonding orbital to the empty bonding orbital of the carbocation. The 1H NMR spectra
of the acid-addition product showed a characteristic proton peak at 4.8 ppm, which
corresponds to the proton at the C4 position of the piperidine ring (Figure 14). This
proton appears more downfield in the acid-addition spectra compared to those from the
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Ritter addition due to the electronegativity of the neighboring heteroatom of the acid,
which pulls electron density away from the proton.
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HN
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27

Figure 14: Acid Addition vs. Ritter Addition
Moreover, the Ritter addition product showed a doublet NH amide peak at 5.78
ppm, which is predictably absent from the acid-addition product spectra. Since the C4
proton in the acid-addition product has four neighboring diastereotopic protons, Pascal’s
triangle results in the equation 24 = 16 meaning that the C4 signal is split into 16 peaks.
However, the equatorial-axial and axial-axial couplings of the two neighboring CH2
groups are similar in nature. The 1H NMR cannot destinguish between the two as
individual peaks, resulting in a triplet of triplets. The 4.6 Hz coupling observed is
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characteristic of equatorial-axial coupling from protons Ha
and Hd. However, the larger triplet is characteristic of
axial-axial coupling (J = 11.6 Hz) from Hb and Hc,
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R
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Ph

indicating that the C4 proton has to be axial (Figure 15). If
the proton were equatorial, we would only see axial-

Figure 15: Acid Addition
Chair Conformation

equatorial and equatorial-equatorial couplings, which are very similar and small
couplings and may result in complex splitting.
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Future Work
These preliminary results have produced racemic mixtures of piperidines
(12R:12S) as standards for future studies that will focus on the use of chiral ligands such
as metal PyBox complexes 28 (Figure 16) to induce asymmetry in the cyclization event.i
The PyBox ligand has a symmetry element that will discriminate between the Re and Si
face of the N-sulfonyliminium ion in the chiral pocket during the cyclization event. By
introducing chirality into the cyclization, we will be able to synthesize only one
enantiomer of the piperidine ring, rather than both,
O

similar to how enzymes catalyze biochemical

O

N
N

M

N

stereospecificity. This method has far-reaching
29

societal implications as many FDA approved
prescription drugs are single enantiomer molecules.

Figure 16: PyBOX Chiral
Ligand

The scientific intellectual caliber of this project will
allow for fundamental understanding of how small molecule “chemozymes” such as 29
desymmetrize achiral molecules such as 10 in cyclization reactions.
Additional future studies will investigate the mechanistic route of the acidaddition product, by performing the Aza Prins/Ritter addition in a non-participatory
solvent such as DCM. This will eliminate the possibility of amide formation, allowing for
the acid catalyst to add to the secondary carbocation without competition. Full
characterization of the acid-addition product can then be performed, as well as isolation
of the crystalline structure.
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SUPPLEMENTAL INFORMATION
6,7-dimethoxy-1-phenethyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline (#). KMB-1-011
Yield: 97.6 mg, 90%; Physical State: white solid; Melting
O
Point: 141-142°C; TLC: Rf = 0.58 (100% CH2Cl2, uv →
O
S
PMA); IR (thin film): cm-1 2999 (CH), 2938 (CH), 2849
N
(CH); 1H NMR (CDCl3, 400 MHz): 𝜹 7.60 (d, 2H, J = 8.0),
7.28 (t, 2H, J = 7.6 Hz), 7.20 (d, 1H. 1H, J = 9.3, 4.4), 3.92
(dt, 2H, J = 13.6 Hz, 3.2 Hz), 3.82 (s, 3H), 3.76 (s, 3H), 3.48
(m, 2H), 2.82 (m, 2H), 2.42 (m, 2H), 2.33 (s, 3H), 2.08 (m,
MeO
2H); 13C {1H} NMR (CDCl3, 100MHz): 𝜹 147.8 (s), 147.5
OMe
(s), 143.0 (s), 141.8 (s), 138.0 (s), 129.4 (d), 128.5 (s), 128.5
(d), 128.4 (d), 127.0 (d), 125.9 (d), 124.6 (s), 111.3 (d), 109.5 (d), 56.2 (d), 56.0 (q), 55.8
(q), 39.2 (t), 38.8 (t), 38.8 (t), 32.9 (t), 25.7 (t), 21.4 (q); HRMS (ESI): Exact mass calcd
for C26H29NO4S [M+Na]+ m/z 474.170950. Found m/z 474.170453.
N-(3,4-dimethoxyphenethyl)-2-nitrobenzenesulfonamide (#). KMB-1-004 Yield: 1.81
g, 90%; Physical State: tan solid; Melting Point: 112-115°C;
TLC: Rf = 0.20 (1:1 Hexanes-Ethyl acetate, uv → PMA); IR (thin
O
O
film): cm-1 3225 (NH), 2939 (CH), 2836 (CH); 1H NMR (400
S
HN
NO2 MHz, CDCl3): 8.07-8.04 (m, 1H), 7.83-7.79 (m, 1H), 7.73-7.65
(m, 2H), 6.64 (dd, 1H, J = 8.4 Hz, 2.0 Hz), 6.71 (d, 1H, J = 8.4
Hz), 6.60 (d, 1H, J = 2.0 Hz), 5.39 (s, 1H), 3.83 (s, 3H), 3.80 (s,
3H), 3.38 (t, 2H, J = 6.8 Hz), 2.78 (t, 2H, J = 6.8 Hz); 13C {1H}
MeO
NMR (100MHz, CDCl3): 149.0 (s), 147.9 (s), 147.8 (s), 133.8 (s),
OMe
133.4 (d), 132.8 (d), 130.8 (d), 129.9 (s), 125.3 (d), 120.8 (d),
111.7 (d), 111.4 (d), 55.9 (d), 55.8 (d), 45.2 (t), 35.6 (t); HRMS (CI): Exact mass calcd
for C18H18N2O6S [M+Na]+ m/z 389.077411. Found m/z 389.077411.
N-(3,4-dimethoxyphenethyl)cyclopropanesulfonamide (#). KMB-1-009 Yield: 924.7
mg, 59%; Physical State: Clear oil; TLC: Rf = 0.4 (1:1 HexanesO
O
Ethyl acetate, uv → PMA); IR (thin film): cm-1 3273 (NH), 2937
S
(CH), 2050 (C=C); 1H NMR (400 MHz, CDCl3): 𝜹 6.82 (d, 1H, J =
HN
8.0 Hz), 6.77-6.73 (m, 2H), 4.25 (t, 1H, J = 6.0 Hz), 3.89 (s, 3H),
3.87 (s, 3H), 3.40 (q, 2H, J = 6.8 Hz), 2.83 (t, 2H, J = 6.8 Hz), 2.34
(tt, 1H, J = 12.8, 8.0, 4.8 Hz), 1.17-1.12 (m, 2H), 0.99-0.94 (m, 2H);
13
MeO
C {1H} NMR (100MHz, CDCl3): 𝜹 149.2 (s), 148.0 (s), 130.3 (s),
OMe
120.8 (d), 112.0 (d), 111.5 (d), 56.0 (q), 55.9 (q), 44.7 (t), 36.2 (t),
30.1 (d), 5.3 (t); HRMS (CI): Exact mass calcd for C13H19NO4S [M+Na]+ m/z
308.092700. Found m/z 308.092663
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N-(3,4-dimethoxyphenethyl)-2-methylpropane-2-sulfinamide (#). DPC-1-014 Yield:
1.00 g, 57%; Physical State: white solid; Melting Point: 93-96°C;
TLC: Rf = 0.50 (4:1 Hexanes-Ethyl acetate, uv → PMA); IR (thin
O
S
film): cm-1 3217 (NH), 2917 (CH), 2856 (CH); 1H NMR (400 MHz,
HN
CDCl3): 6.81 (d, 1H, J = 8.6 Hz), 6.76 (d, 1H, J = 1.8 Hz), 6.74 (d,
1H, J = 1.8 Hz), 3.87 (s, 3H), 3.87 (s, 3H), 3.44 (ddd, 1H, J = 19.5,
12.8, 6.7 Hz), 3.32 (ddd, 1H, J = 13.8, 6.7 Hz), 3.22 (t, 1H, J = 6.2
Hz), 2.84 (dp, 2H, J = 13.8, 6.7 Hz), 1.18 (s, 9H); 13C {1H} NMR
MeO
(100MHz, CDCl3): 149.0 (s), 147.7 (s), 131.1 (s), 120.9 (d), 112.2
OMe
(d), 111.3 (d), 55.9 (q), 55.9 (q), 55.7 (s), 47.2 (t), 47.2 (t), 37.1 (t),
22.6 (q); HRMS (CI): Exact mass calcd for C14H23NO3S [M+Na]+ m/z 308.129085.
Found m/z 308.128800.
N-(3,4-dimethoxyphenethyl)-2-methylpropane-2-sulfonamide (#). DPC-1-015 Yield:
926 mg, 88%; Physical State: white solid; Melting Point: 106O
O
108°C; TLC: Rf = 0.51 1H NMR (400 MHz, CDCl3): 6.82 (s, 1H),
S
6.77 (d, 1H, J = 8.0 Hz), 6.74 (d, 1H, J = 8.0), 3.88 (s, 3H), 3.82 (s,
HN
3H), 3.57 (t, 1H, J = 6.0 Hz), 3.41 (q, 2H, J = 6.7 Hz), 2.83 (t, 2H, J
= 7.7 Hz), 1.36 (s, 9H); 13C {1H} NMR (100MHz, CDCl3): 149.2 (s),
147.9 (s), 130.4 (s), 120.9 (d), 112.1 (d), 111.5 (d), 59.9 (s), 56.0 (q),
55.9 (q), 46.2 (t), 37.2 (t), 24.3 (q); HRMS (CI): Exact mass calcd for
MeO
C14H23NO4S [M+Na]+ m/z 324.124000. Found m/z 324.123812
OMe
2-(cyclopropylsulfonyl)6,7-dimethoxy-1-phenethyl-1,2,3,4-tetrahydroisoquinoline
(#). GJR-5-024 Yield: 101.3 mg, 89%; Physical State: clear oil; TLC:
O
Rf = 0.6 (100% dichloromethane, uv → PMA); IR (thin film): cm-1
S O
3000 (CH), 2936 (CH); 1H NMR (CDCl3, 400 MHz): 𝜹 7.30-7.23 (m,
N
Ph
4H), 7.19-7.16 (m, 1H), 6.58 (s, 1H), 6.42 (s, 1H), 4.78 (dd, 1H, J =
10.0, 4.0 Hz), 4.01 (dd, 1H, J = 15.2, 4.0 Hz), 3.84 (s, 3H), 3.82 (s, 3H),
3.51 (ddd, 1H, J = 17.2, 12.0, 5.2 Hz), 3.07 (ddd, 1H, J = 16.8, 12.0,
6.8), 2.91-2.79 (m, 2H), 2.68 (dd, 1H, J = 16.8, 4.0 Hz), 2.20-1.98 (m,
MeO
3H), 1.19-1.17 (m, 1H), 1.10-1.06 (m, 1H), 0.85-0.81 (m, 1H), 0.75OMe
0.71 (m, 1H); 13C {1H} NMR (CDCl3, 100MHz): 𝜹 148.0 (s), 147.7
(s), 141.8 (s), 129.1 (d), 128.5 (d), 128.4 (d), 125.9 (s), 124.5 (s), 111.6 (d), 109.5 (d), 56.1
(d), 56.0 (q), 55.9 (q), 38.9 (t), 38.5 (t), 32.9 (t), 30.2 (d), 26.7 (t), 5.7 (t), 5.4 (t); HRMS
(ESI): Exact mass calcd for C22H27NO4S [M+Na]+ m/z 424.155300. Found m/z
424.155336.
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2-(mesitylsulfonyl)-6,7-dimethoxy-1-phenethyl-1,2,3,4-tetrahydroisoquinoline
(#).
GJR-5-009 Yield: 55.8 mg, 49%; Physical State: clear oil; TLC: Rf =
-1
O
O 0.48 (100% Dichloromethane, uv → PMA); IR (thin film): cm 2937
S
(CH), 1735 (C=C); 1H NMR (CDCl3, 400 MHz): 𝜹 7.23 (td, 2H, J = 7.6,
Ph
N
1.2 Hz), 7.15 (tt, 1H, J = 7.6, 1.2 Hz), 7.03 (dd, 2H, J = 4.4, 1.2 Hz), 6.95
(s, 2H), 6.53 (s, 1H), 6.46 (s, 1H), 4.66 (q, 1H, J = 4.4 Hz), 3.89 (dd, 1H,
J = 9.2, 6.0 Hz), 3.82 (s, 3H), 3.81 (s, 3H), 3.44 (ddd, 1H, J = 14.0, 12.0,
4.4 Hz), 2.81 (ddd, 1H, J = 16.4, 12.0, 6.4 Hz), 2.62 (ddd, 1H, J = 14.0,
MeO
10.8, 5.2), 2.59 (s, 6H), 2.58-2.50 (m, 1H), 2.37-2.32 (m, 1H), 2.30 (s,
OMe
3H), 2.10 (m, 1H), 1.99 (m, 1H); 13C {1H} NMR (CDCl3, 100MHz): 𝜹
147.9 (s), 147.8 (s), 142.4 (s), 141.6 (s), 140.2 (s), 133.6 (s), 132.0 (d), 128.9 (s), 128.4 (d),
128.3 (d), 125.9 (d), 125.2 (s), 111.7 (d), 109.6 (d), 56.0 (d), 55.8 (q), 55.7 (q), 38.9 (t),
38.2 (t), 32.6 (t), 27.2 (t), 23.0 (q), 21.1 (s); HRMS (ESI): Exact mass calcd for
C28H33NO4S [M+Na]+ m/z 502.202250. Found m/z 502.201585.
1-ethyl-6,7-dimethoxy-2-tosyl-1,2,3,4-tetrahydroisoquinoline (#). DPC-1-030 Yield:
108.2 mg, 97%; Physical State: clear oil; TLC: Rf = 0.29 (2:1
O
Hexanes-Ethyl acetate, uv → PMA); IR (thin film): cm-1 2965
O
S
(CH), 2933 (CH); 1H NMR (CDCl3, 400 MHz): 𝜹 7.59 (d, 2H,
J = 8.0 Hz), 7.11 (d, 2H, J = 8.0 Hz), 6.53 (s, 1H), 6.34 (s,
N
1H), 4.81 (dd, 1H, J = 8.4, 6.4 Hz), 3.86 (s, 3H), 3.85 (m, 1H),
3.77 (s, 3H), 3.40 (ddd, 1H, J = 14.4, 9.6, 6.8 Hz), 2.41 (m,
2H), 2.33 (s, 3H), 1.79 (m, 2H), 1.79 (m, 2H), 1.04 (t, 3H, J =
MeO
7.6 Hz); 13C {1H} NMR (CDCl3, 100MHz): 𝜹 148.0 (s), 147.7
OMe
(s), 141.8 (s), 129.1 (d), 128.5 (d), 128.4 (d), 125.9 (s), 124.5
(s), 111.6 (d), 109.5 (d), 56.1 (d), 56.0 (q), 55.9 (q), 38.9 (t), 38.5 (t), 32.9 (t), 30.2 (d),
26.7 (t), 5.7 (t), 5.4 (t); HRMS (ESI): Exact mass calcd for C20H25NO4S [M+Na]+ m/z
398.139650. Found m/z 398.139658.
1-butyl-6,7-dimethoxy-2-tosyl-1,2,3,4-tetrahydroisoquinoline (#). EBC-4-042 Yield:
10.6 mg, 22%; Physical State: clear oil; TLC: Rf = 0.75 (9:1
Dichloromethane-Ethyl acetate, uv → PAA); IR (thin film):
O
O
cm-1 2921 (CH), 2361 (C-H); 1H NMR (CDCl3, 400 MHz): 𝜹
S
7.58 (d, 2H, J = 8.0 Hz), 7.11 (d, 2H, J = 8.0 Hz), 6.51 (s, 1H),
N
6.33 (s, 1H), 4.87 (dd, 1H, J = 9.5, 4.8 Hz), 3.87 (m, 1H), 3.86
(s, 3H), 3.77 (s, 3H), 3.42 (ddd, 1H, J = 14.5, 9.8, 6.8 Hz),
2.41 (dd, 2H, J = 6.5, 3.5 Hz), 2.33 (s, 3H), 1.73 (m, 2H),
MeO
1.40-1.34 (m, 4H), 0.90 (t, 3H, J = 7.2 Hz); 13C {1H} NMR
OMe
(CDCl3, 100MHz): 𝜹 147.7 (s), 147.4 (s), 142.9 (s), 138.1 (s),
129.3 (d), 129.1 (s), 127.0 (d), 124.6 (s), 111.3 (d), 109.6 (d), 56.4 (d), 56.0 (q), 55.8 (s),
38.5 (t), 37.3 (t), 28.7 (t), 25.7 (t), 22.5 (t), 21.4 (q), 14.0 (q); HRMS (ESI): Exact mass
calcd for C22H29NO4S [M]+ m/z 426.17950. Found m/z 426.170556.
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1-pentyl-6,7-dimethoxy-2-tosyl-1,2,3,4-tetrahydroisoquinoline (#). DPC-1-027 Yield:
132.3 mg, quant.; Physical State: clear oil.; TLC: Rf = 0.42
(100% dichloromethane, uv → PMA); IR (thin film): cm-1
O
O
2925 (CH), 2854 (CH); 1H NMR (CDCl3, 400 MHz): 𝜹
S
7.58 (d, 2H, J = 8.0 Hz), 7.10 (d, 2H, J = 8.0 Hz), 6.51 (s,
N
1H), 6.33 (s, 1H), 4.87 (dd, 1H, J = 8.8, 4.8 Hz), 3.89 (ddd,
1H, J = 4.8, 2.4, 1.6 Hz), 3.86 (s, 3H), 3.77 (s, 3H), 3.41
(ddd, 1H, J = 14.8, 10.4, 6.4 Hz), 2.45-2.39 (m, 2H), 2.32 (s,
MeO
3H), 1.71 (m, 2H), 1.49-1.41 (m, 2H), 1.36-1.27 (m, 4H),
OMe
0.88 (t, 3H, J = 7.2 Hz); 13C {1H} NMR (CDCl3, 100MHz):
𝜹 147.7 (s), 147.3 (s), 142.9 (s), 138.1 (s), 129.3 (d), 129.1 (s), 127.0 (d), 124.6 (s), 111.3
(d), 109.6 (d), 56.4 (d), 56.0 (q), 55.8 (q), 38.5 (t), 37.5 (t), 31.6 (t), 26.2(t), 25.8 (t), 22.6
(t), 21.4 (q), 14.1 (q); HRMS (CI): Exact mass calcd for C23H31NO4S [H]+ m/z
418.204656. Found m/z 418.204840.
1-cyclohexyl-6,7-dimethoxy-2-tosyl-1,2,3,4-tetrahydroisoquinoline (#). KMB-1-043
Yield: 97.6 mg, 95%; Physical State: clear oil; TLC: Rf =
O
0.40 (100% dichloromethane, uv → PMA); IR (thin film): cmO S
1
3272 (NH), 2938 (CH); 1H NMR (CDCl3, 400 MHz): 𝜹 7.47
N
(d, 2H, J = 8.0 Hz), 7.03 (d, 2H, J = 8.0 Hz), 6.48 (s, 1H), 6.30
(s, 1H), 4.51 (d, 1H, J = 8.8 Hz), 3.85 (s, 3H), 3.75 (s, 3H),
3.72 (ddd, 1H, J = 13.5, 7.2, 6.8 Hz), 3.54 (ddd, 1H, J = 14.4,
9.2, 5.6 Hz), 2.54 (ddd, 1H, J = 16.4, 6.0, 4.4 Hz), 2.38 (ddd,
MeO
1H, 16.4, 8.0, 4.4 Hz), 2.29 (s, 3H), 2.10-2.00 (m, 2H), 1.81OMe
1.60 (m, 5H), 1.71-1.10 (m, 2H); 13C {1H} NMR (CDCl3,
100MHz): 𝜹 147.8 (s), 145.5 (s), 142.7 (s), 137.4 (s), 129.0 (d), 127.4 (s), 127.3 (d),
125.1 (s), 111.5 (d), 111.3 (d), 61.8 (d), 56.1 (q), 55.8 (q), 42.9 (d), 39.6 (t), 30.7 (t), 30.4
(t), 26.3 (t), 26.2 (t), 25.3 (t), 21.4 (q); HRMS (ESI): Exact mass calcd for C24H31NO4S
[M+Na]+ m/z 452.186600. Found m/z 452.186723.
1-(benzyloxy)methyl)-6,7-dimethoxy-2-tosyl-1,2,3,4-tetrahydroisoquinoline (#).
GJR-5-023 Yield: 98.5 mg, 88%; Physical State: clear
O
oil; TLC: Rf = 0.68 (100% dichloromethane, uv →
O
PMA); IR (thin film): cm-1 2935 (CH), 2861 (CH); 1H
S
NMR (CDCl3, 400 MHz): 𝜹 7.69 (d, 2H, J = 8.4 Hz),
N
O
7.34-7.20 (m, 5H), 7.14 (d, 2H, J = 8.4 Hz), 6.61 (s, 1H),
6.46 (s, 1H), 5.13 (t, 1H, J = 3.2 Hz), 4.53 (d, 1H, J =
12.0 Hz), 4.44 (d, 1H, J = 12.0 Hz), 3.82-3.77 (m, 2H),
MeO
3.79 (s, 3H), 3.77 (s, 3H), 3.66 (dd, 1H, J = 9.6, 3.2 Hz),
OMe
3.48 (ddd, 1H, J = 14.0, 11.2, 4.8 Hz), 2.71-2.50 (m, 1H),
2.50 (dt, 1H, J = 12.0, 4.0 Hz); 13C {1H} NMR (CDCl3, 100MHz): 𝜹 148.0 (s), 147.3 (s),
143.1 (s), 138.0 (s), 137.8 (s), 129.4 (d), 128.3 (d), 127.6 (d), 127.6 (d), 127.2 (d), 126.1
(s), 125.2 (s), 111.3 (d), 110.2 (d), 73.7 (t), 73.0 (t), 55.9 (q), 55.8 (q), 55.2 (d), 40.1 (t),
27.0 (t); HRMS (CI): Exact mass calcd for C26H29NO5S [M+Na]+ m/z 490.165865.
Found m/z 490.166085
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1-cyclopropyl-6,7-dimethoxy-2-tosyl-1,2,3,4-tetrahydroisoquinoline (#). DPC-1-028
Yield: 67 mg, 58%; Physical State: clear oil; TLC: Rf = 0.40
(100% dichloromethane, uv → PMA); IR (thin film): cm-1 3003
O
O
(CH), 2934 (CH), 2835 (CH); 1H NMR (CDCl3, 400 MHz): 𝜹
S
7.59 (d, 2H, J = 7.6 Hz), 7.13 (d, 2H, J = 7.6 Hz), 6.63 (s, 1H),
N
6.38 (s, 1H), 4.37 (d, 1H, J = 8.0 Hz), 3.90 (m, 1H), 3.86 (s, 3H),
3.79 (s, 3H), 3.61 (ddd, 1H, J = 16.8, 10.4, 6.4 Hz), 2.50 (m,
2H), 2.34 (s, 3H), 1.21 (m, 1H), 0.68 (m, 1H), 0.56 (m, 3H); 13C
MeO
{1H} NMR (CDCl3, 100MHz): 𝜹 148.0 (s), 147.2 (s), 142.9 (s),
OMe
138.2 (s), 129.3 (d), 127.9 (s), 127.0 (d), 125.0 (s), 111.3 (d),
110.0 (d), 60.0 (d), 56.0 (q), 55.8 (q), 39.4 (t), 26.3 (t), 21.4 (q), 18.3 (d), 5.6 (t), 3.5 (t);
HRMS (ESI): Exact mass calcd for C21H25NO4S [M+Na]+ m/z 410.139650. Found m/z
410.138845.
Ethyl-6,7-dimethoxy-2-tosyl-1,2,3,4-tetrahydroisoquinoline-1-carboxylate (#). GJR4-008 Yield: 26.3 mg, 26%; Physical State: clear oil; TLC: Rf
= 0.4 (100% CH2Cl2, uv → PMA); IR (thin film): cm-1 2936
O
O
(CH), 2255 (C=C), 1735 (C=O); 1H NMR (CDCl3, 400 MHz):
S
O
𝜹 7.71 (d, 2H, J = 8.0 Hz), 7.27 (d, 2H, J = 8.0 Hz), 6.90 (s, 1H),
N
EtO
6.55 (s, 1H), 5.45 (s, 1H), 4.02 (dq, 2H, J = 14.4, 7.2, 1.6 Hz),
3.84 (s, 3H), 3.83 (s, 3H), 3.80 (ddd, 2H, J = 16.0, 10.0, 6.4 Hz),
2.81 (dt, 2H, J = 16.0, 5.6 Hz), 2.41 (s, 3H), 1.17 (t, 3H, J = 8.0
MeO
Hz); 13C {1H} NMR (CDCl3, 100MHz): 𝜹 170.5 (s), 148.7 (s),
OMe
147.7 (s), 143.5 (s), 136.7 (s), 129.6 (d), 127.2 (d), 126.3 (s),
121.5 (s), 111.4 (d), 109.9 (d), 61.5 (t), 57.4 (d), 56.0 (q), 55.9 (q), 40.8 (t), 27.9 (t), 21.5
(q), 14.0 (q); HRMS (ESI): Exact mass calcd for C21H25NO6S [M]+ m/z 420.147535.
Found m/z 420.146935.
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